Unclaimed brand
Discover long-acting injectable treatment options for adults with bipolar I disorder or schizophrenia. See Important Safety Info & Full Prescribing Info, including Boxed WARNING.
Liking this brand profile? Share this page
Hex Code
Color name
RGB
HSL
CMYK
#0086A1
Deep Cerulean
0, 134, 161
190, 100, 32
100, 17, 0, 37
#A8B8D7
Pigeon Post
168, 184, 215
220, 37, 75
22, 14, 0, 16
#002B3A
Daintree
0, 43, 58
196, 100, 11
100, 26, 0, 77
ABILIFY ASIMTUFII® (aripiprazole) is a leading brand in psychiatric treatment, providing innovative solutions for individuals battling mental health disorders. Specifically designed for adults, ABILIFY ASIMTUFII® is used as a maintenance treatment for schizophrenia and bipolar I disorder. This injectable medication offers a groundbreaking approach with its once-monthly dosing, allowing for longer-lasting symptom control and ease of adherence to treatment regimens.
In addition to ABILIFY ASIMTUFII®, the brand features ABILIFY MAINTENA®, which provides a similar extended-release option for those managing these complex conditions. These medications aim to enhance the quality of life for patients by stabilizing mood and reducing the frequency of episodes associated with their diagnoses.
The brand emphasizes safety and effectiveness, urging patients to collaborate closely with healthcare providers to ensure tolerability and monitor potential side effects. Furthermore, the safety information highlights the importance of awareness of risks, especially among specific populations, ensuring that ABILIFY remains a trusted choice for mental health management.
Brand industry
Health
Company type
Suggest company type
Year founded
Suggest founded year
Company size
Suggest company size
Long-acting aripiprazole injections
Bipolar I maintenance treatment
Schizophrenia maintenance treatment
Two-month antipsychotic injections
